Arsenic trioxide as intravascular or oral agent used in patients with Acute promyelocytic leukemia

The determination and comparison of plasma concentration of arsenic trioxide as intravascular and oral agent used in patients with Acute promyelocytic leukemia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138710271030N4

Enrollment

Registered

2009-03-09

Start date

2009-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute promyelocytic leukemia. Acute promyelocytic leukemia

Interventions

Intervention 1: At first day: Arsenic trioxide, 10 mg, capsule. Intervention 2: At second day: Arsenic trioxide, 10 mg, infusion.

Treatment - Drugs

At first day: Arsenic trioxide, 10 mg, capsule

At second day: Arsenic trioxide, 10 mg, infusion

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Acute promyelocytic leukemia type M3, complete remission, not receiving any marine foods during last week, normal cardiopulmonary and renal function. Exclusion Criteria: Less than 16 years old, Impaired cardiopulmonary and renal function.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Plasma concentration of arsenic trioxide. Timepoint: 0,1,2,3,4,6,8,24,25,26,27,28,30,32,48h after initiation of therapy. Method of measurement: Atomic Absorption of Arsenic.	—

Secondary

Measure	Time frame
Side effects. Timepoint: During the study. Method of measurement: History taking and physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAliarash Anoushiravani

Hematology-Oncology and SCT Research Center

anoush_aa@yahoo.com+98 21 8490 2635

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026